Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Smrithi Jayashree Satheeshkumar has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • Abhirupa Kar

    SOLi3D Laboratory, Tata Translational Cancer Research Centre, Tata Medical Center, New Town, 14 MAR (E-W), Kolkata, 700160, India

    2 shared publications
  • Anindita Dutta

    SOLi3D Laboratory, Tata Translational Cancer Research Centre, Tata Medical Center, New Town, 14 MAR (E-W), Kolkata, 700160, India

    2 shared publications
  • Dipjit Basak

    SOLi3D Laboratory, Tata Translational Cancer Research Centre, Tata Medical Center, New Town, 14 MAR (E-W), Kolkata, 700160, India

    2 shared publications
  • Manas Kumar Roy

    Department of Gastrointestinal and Hepatobiliary Surgery, Tata Medical Center, Kolkata, India

    2 shared publications
  • Pritha Banerjee

    SOLi3D Laboratory, Tata Translational Cancer Research Centre, Tata Medical Center, New Town, 14 MAR (E-W), Kolkata, 700160, India

    2 shared publications
  • Rajgopal Srinivasan

    TCS Research, Tata Consultancy Services, Hyderabad, India

    2 shared publications

Latest Publications

  • An Annotated Living Organoid Biobank for Studying Gallbladder Diseases and Drug Responses

    by Ankita Dutta, Nandita Chowdhury, Akshaya Vijayan Selvarajan, Payel Guha, Pritha Banerjee, Abhirupa Kar, Uma Sunderam, Debdutta Ganguli, Trina Dutta, Dipjit Basak, et al.

    Gallbladder cancer (GBC) while rare worldwide has a high prevalence in India. Pathogenesis is unclear and outcomes poor. No suitable models are available to study GBC pathogenesis and drug response. The aim of this study was to establish a biobank comprising patient derived organoids (PDOs) from a wide variety of gallbladder diseases including GBC and other rare pathologies. PDOs were developed from surgically resected gallbladders 15 normal; 58 inflamed; 12 xanthogranulomatous cholecystitis (XGC); 5 pre-invasive neoplasm (PIN); and 13 invasive malignant gallbladder pathologies. Marker expressions, functional activity, histological and gene expression analyses were performed to validate the models. Banked PDOs were retrieved and drug assays performed to assess line-specific responses. Protocol optimization achieved 58% (69/119) and 52% (10/19) success in organoid generation and expansion for all and invasive malignant pathologies, respectively-highest globally for GBC organoids reported to date. Organoids maintained tight junction integrity; P-gp pump and enzymatic activity; preserved tissue-specific gene and protein marker expression; histological features and genetic variations. Besides cryopreserved organoids from 62 patients, primary gallbladder tissue and high-quality DNA, RNA and protein derivatives have been banked. In gene expression analyses of tissue, XGC samples clustered with malignant subtypes, separate from benign pathologies. Derived XGC organoids showed a similar clustering. Enriched Hallmark pathways in XGC support neoplastic changes. Drug response assays demonstrate PDO line-specific response heterogeneity. The developed biobank of PDOs from different gallbladder pathologies provides a promising resource to study gallbladder diseases, investigate the pathogenesis of GBC and study drug responses.


  • Open Access

    Insights into gallbladder cancer pathogenesis from a living organoid gallbladder cholangiocyte biorepository

    by Ankita Dutta, Nandita Chowdhury, Akshaya Vijayan Selvarajan, Pritha Banerjee, Abhirupa Kar, Shinjini Chandra, Uma Sunderam, Debdutta Ganguli, Trina Dutta, Dipjit Basak, et al.

    Gallbladder cancer (GBC) while rare worldwide has a high prevalence in India. Pathogenesis is unclear and outcomes poor. Gallbladder cholangiocyte organoids (GCOs) or gallbladder carcinoma organoids (GBCOs) were developed and serially propagated from surgically resected gallbladder tissues with benign or malignant diseases, respectively. Patient derived organoids (PDOs) were derived from 15 normal; 58 inflamed; 12 xanthogranulomatous cholecystitis (XGC); 5 pre-invasive neoplasm and 13 invasive malignant gallbladder pathologies. Protocol optimisation achieved 58% (69/119) success in organoid generation and expansion. Organoids maintained tight junction integrity; P-gp pump and enzymatic activity; preserved tissue-specific gene and protein marker expression; histological features and genetic variations. Cryopreserved organoids from 62 patients with primary tissue and high-quality DNA, RNA and protein derivatives have been banked. In gene expression analyses of tissue, XGC samples clustered with malignant subtypes, separate from benign pathologies. Derived XGC organoids showed a similar clustering. Enriched hallmark pathways in XGC support neoplastic change through chronic inflammation. PDOs generated from different gallbladder pathologies are a promising model to investigate the pathogenesis of GBC. Graphical

  • Open Access

    Peptide Vaccines as Therapeutic and Prophylactic Agents for Female-Specific Cancers: The Current Landscape

    by Manju Lekshmy, Chandrasekharan Rajalekshmi Dhanya, Jayashree SatheeshKumar Smrithi, Janaki Anandavallyamma Sindhurani, Jiji Joseph Vandanamthadathil, Jayakrishnan Therthala Veettil, Leelamma Anila, Vishnu Sasidharan Lathakumari, Adhira M. Nayar, Maya Madhavan

    Breast and gynecologic cancers are significant global threats to women’s health and those living with the disease require lifelong physical, financial, and social support from their families, healthcare providers, and society as a whole. Cancer vaccines offer a promising means of inducing long-lasting immune response against the disease. Among various types of cancer vaccines available, peptide vaccines offer an effective strategy to elicit specific anti-tumor immune responses. Peptide vaccines have been developed based on tumor associated antigens (TAAs) and tumor specific neoantigens which can also be of viral origin. Molecular alterations in HER2 and non-HER2 genes are established to be involved in the pathogenesis of female-specific cancers and hence were exploited for the development of peptide vaccines against these diseases, most of which are in the latter stages of clinical trials. However, prophylactic vaccines for viral induced cancers, especially those against Human Papillomavirus (HPV) infection are well established. This review discusses therapeutic and prophylactic approaches for various types of female-specific cancers such as breast cancer and gynecologic cancers with special emphasis on peptide vaccines. We also present a pipeline for the design and evaluation of a multiepitope peptide vaccine that can be active against female-specific cancers.